Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment

(2011) P. Hadji et al.   ANNALS OF ONCOLOGY

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

The science behind vitamins and natural compounds for breast cancer prevention. Getting the most prevention out of it

(2011) Matteo Lazzeroni et al.   BREAST

New developments for treatment and prevention of bone metastases

(2011) Jean-Jacques Body   CURRENT OPINION IN ONCOLOGY

Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline

(2011) Michael F. Holick et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older

(2011) Andrew N. Freedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial

(2011) Michael Gnant et al.   LANCET ONCOLOGY

Breast-Cancer Adjuvant Therapy with Zoledronic Acid

(2011) Robert E. Coleman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study

(2010) H. Eidtmann et al.   ANNALS OF ONCOLOGY

Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial

(2010) R. Eastell et al.   ANNALS OF ONCOLOGY

Cortical and trabecular bone at the radius and tibia in postmenopausal breast cancer patients: A Peripheral Quantitative Computed Tomography (pQCT) study

(2010) K.A. Szabo et al.   BONE

Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study

(2010) Robert E. Coleman et al.   BREAST CANCER RESEARCH AND TREATMENT

Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study

(2010) Daniel Prieto-Alhambra et al.   BREAST CANCER RESEARCH AND TREATMENT

Assessment of fracture risk in women with breast cancer using current vs emerging guidelines

(2010) P Hadji et al.   BRITISH JOURNAL OF CANCER

Satisfaction With Initial Screen and Compliance With Biennial Breast Screening at Centers With and Without Nurses

(2010) Sarah A. Edwards et al.   CANCER NURSING

Emerging drugs for the management of cancer treatment induced bone loss

(2010) Francesco Bertoldo et al.   EXPERT OPINION ON EMERGING DRUGS

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

The diagnosis of osteoporosis

(2010) John A. Kanis et al.   JOURNAL OF BONE AND MINERAL RESEARCH

American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

(2010) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial

(2010) Catherine Van Poznak et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

(2010) Jack Cuzick et al.   LANCET ONCOLOGY

Women and Bone Health: Maximizing the Benefits of Aromatase Inhibitor Therapy

(2010) Shou-Ching Tang   ONCOLOGY

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

(2009) M. Rabaglio et al.   ANNALS OF ONCOLOGY

Prevention of Nonvertebral Fractures With Oral Vitamin D and Dose Dependency

(2009) Heike A. Bischoff-Ferrari et al.   ARCHIVES OF INTERNAL MEDICINE

Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer

(2009) Mirieme Ghazi et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Update of the BIG 1–98 Trial: Where do we stand?

(2009) Markus Joerger et al.   BREAST

Meta-analysis of vitamin D, calcium and the prevention of breast cancer

(2009) Peizhan Chen et al.   BREAST CANCER RESEARCH AND TREATMENT

Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study

(2009) Georgiana K. Ellis et al.   BREAST CANCER RESEARCH AND TREATMENT

Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results

(2009) Adam M. Brufsky et al.   Clinical Breast Cancer

FRAX and Risk of Vertebral Fractures: The Fracture Intervention Trial

(2009) Meghan G Donaldson et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

(2009) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

(2009) Michael Gnant et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bisphosphonates in Oncology: Rising Stars or Fallen Heroes

(2009) T. Van den Wyngaert et al.   ONCOLOGIST

Benefit–risk assessment of vitamin D supplementation

(2009) H. A. Bischoff-Ferrari et al.   OSTEOPOROSIS INTERNATIONAL

Global vitamin D status and determinants of hypovitaminosis D

(2009) A. Mithal et al.   OSTEOPOROSIS INTERNATIONAL

Practical guidance for the management of aromatase inhibitor-associated bone loss

(2008) P. Hadji et al.   ANNALS OF ONCOLOGY

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole

(2008) Nigel J. Bundred et al.   CANCER

Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group

(2008) David M. Reid et al.   CANCER TREATMENT REVIEWS

Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer

(2008) J. E. Lester et al.   CLINICAL CANCER RESEARCH

Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

(2008) Susan L. Greenspan et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230

(2008) Richard Eastell et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer

(2008) Stephanie L. Hines et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

(2008) Michael Gnant et al.   LANCET ONCOLOGY

Vitamin D deficiency: a global perspective

(2008) Ann Prentice   NUTRITION REVIEWS

Integrated Analysis of Zoledronic Acid for Prevention of Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole

(2008) A. Brufsky et al.   ONCOLOGIST

Vitamin D status and response to treatment in post-menopausal osteoporosis

(2008) S. Adami et al.   OSTEOPOROSIS INTERNATIONAL

FRAX™ and the assessment of fracture probability in men and women from the UK

(2008) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL